Cargando…
The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids
Monoagent DNA-alkylating chemotherapies like dacarbazine are among a paucity of medical treatments for advanced carcinoid tumors, but are limited by host toxicity and intrinsic chemoresistance through the base excision repair (BER) pathway via poly (ADP-ribose) polymerase (PARP). Hence, inhibitors o...
Autores principales: | Somnay, Yash, Lubner, Sam, Gill, Harpreet, Matsumura, Jon Blake, Chen, Herbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083201/ https://www.ncbi.nlm.nih.gov/pubmed/27632933 http://dx.doi.org/10.1038/cgt.2016.39 |
Ejemplares similares
-
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
por: Guillot, Clément, et al.
Publicado: (2014) -
PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
por: Mariano, Germano, et al.
Publicado: (2015) -
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016) -
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
por: Yuan, Alice L., et al.
Publicado: (2018) -
Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration
por: Hastings, Lyndsay, et al.
Publicado: (2022)